☰

Jason G. Harb, Ph.D. - Publications

Affiliations: 
2004 University of Wisconsin-Milwaukee, Milwaukee, WI 
Area:
Analytical Chemistry
Tree Info Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Silvestri G, Stramucci L, Ellis J, Harb J, Neviani P, Zhang B, Srutova K, Pineda G, Jamieson C, Calabretta B, Stagno F, Vigneri P, Nteliopoulos G, May P, Reid A, et al. Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance Cancer Research. 78: 1134-1134. DOI: 10.1158/1538-7445.Am2018-1134  0.367
2015 Silvestri G, Stramucci L, Ellis J, Yu J, Harb J, Neviani P, Marcucci G, Srutova K, Machova Polakova K, Roy D, Hokland P, Deininger MW, Bhatia R, Gambacorti-Passerini C, Milojkovic D, et al. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML Blood. 126: 53-53. DOI: 10.1182/Blood.V126.23.53.53  0.388
2014 Silvestri G, Ellis J, Stramucci L, Harb JG, Neviani P, Marcucci G, Roy D, Hokland P, Milojkovic D, Reid A, Apperley JF, Livak FM, Baer MR, Trotta R, Perrotti D. MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay Blood. 124: 4529-4529. DOI: 10.1182/Blood.V124.21.4529.4529  0.416
2013 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951  0.386
2013 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 122: 3034-44. PMID 23970380 DOI: 10.1182/Blood-2013-04-495374  0.407
2013 Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/Blood-2013-03-492181  0.377
2013 Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia. 27: 1996-2005. PMID 23670294 DOI: 10.1038/Leu.2013.151  0.413
2013 Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of Hematology & Oncology. 6: 21. PMID 23497456 DOI: 10.1186/1756-8722-6-21  0.35
2012 Magistroni V, Sharma N, Piazza R, Harb JG, Spinelli R, Pirola A, Ellis J, Dong-Wook K, Perrotti D, Gambacorti-Passerini C. Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia Blood. 120: 3727-3727. DOI: 10.1182/Blood.V120.21.3727.3727  0.361
2012 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis J, Marcucci G, Landesman Y, Shacham S, Kauffman M, Perrotti D. Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL Blood. 120: 35-35. DOI: 10.1182/Blood.V120.21.35.35  0.444
2012 Walker C, Oaks JJ, Santhanam R, Neviani P, Harb JG, Paisie C, Marcucci G, Landesman Y, Shacham S, Kauffman M, Perrotti D. Abstract 3839: Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias Cancer Research. 72: 3839-3839. DOI: 10.1158/1538-7445.Am2012-3839  0.44
2011 Perrotti D, Harb JG. BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention. Leukemia & Lymphoma. 52: 30-44. PMID 21299458 DOI: 10.3109/10428194.2010.546914  0.371
2011 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Paisie C, Marcucci G, Shacham S, Kauffman M, Perrotti D. Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity, Blood. 118: 3758-3758. DOI: 10.1182/Blood.V118.21.3758.3758  0.453
2011 Harb JG, Neviani P, Huettner CS, Marcucci G, Perrotti D. Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1+in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34+/CD38− Stem and CD34+ progenitor Cells From CML-BC Patients Blood. 118: 2738-2738. DOI: 10.1182/Blood.V118.21.2738.2738  0.447
2011 Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Neviani P, Harb JG, Ogretmen B, Bittman R, Levine RL, Quintás-Cardama A, Marcucci G, Perrotti D. FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration Blood. 118: 2494-2494. DOI: 10.1182/Blood.V118.21.2494.2494  0.4
2011 Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109  0.392
2010 Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-65. PMID 20211135 DOI: 10.1016/J.Cell.2010.01.007  0.341
2010 Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Walker C, Neviani P, Harb JG, Ma Y, Verstovsek S, Marcucci G, Briesewitz R, Bittman R, Chen C, Quintas-Cardama A, Ogretmen B, et al. Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders Blood. 116: 775-775. DOI: 10.1182/Blood.V116.21.775.775  0.421
2010 Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515  0.408
2010 Walker C, Oaks JJ, Neviani P, Harb JG, Santhanam R, Ma Y, Marcucci G, Van Brocklyn J, Chen C, Bittman R, Perrotti D. PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives Blood. 116: 2901-2901. DOI: 10.1182/Blood.V116.21.2901.2901  0.429
2010 Harb JG, Neviani P, Oaks JJ, Marcucci G, Hokland P, Roy D, Perrotti D. The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML. Blood. 116: 1222-1222. DOI: 10.1182/Blood.V116.21.1222.1222  0.351
2010 Eiring AM, Harb J, Neviani P, Oaks JJ, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, et al. Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors Cancer Research. 70: 1950-1950. DOI: 10.1158/1538-7445.Am10-1950  0.343
2009 Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 114: 1374-82. PMID 19520806 DOI: 10.1182/Blood-2009-05-220814  0.347
2009 Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, et al. Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors. Blood. 114: 855-855. DOI: 10.1182/Blood.V114.22.855.855  0.337
2009 Harb J, Neviani P, Huettner C, Marcucci G, Perrotti D. BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells. Blood. 114: 191-191. DOI: 10.1182/Blood.V114.22.191.191  0.404
2008 Harb JG, Chyla BI, Huettner CS. Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood. 111: 3760-9. PMID 18216295 DOI: 10.1182/Blood-2007-08-108803  0.376
2007 Harb JG, Chyla BI, Huettner CS. A Novel Role for Bcl-xL in the Context of p210 BCR/ABL B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 110: 156-156. DOI: 10.1182/Blood.V110.11.156.156  0.381
2007 Chyla BJ, Harb JG, Huettner CS. Loss of Bcl-x Does Not Ameliorate Chronic Myeloid Leukemia in an Inducible Murine Model System. Blood. 110: 1000-1000. DOI: 10.1182/Blood.V110.11.1000.1000  0.405
2006 Chyla BJ, Harb JG, Huettner CS. Genetic Deletion of Bcl-x Reveals a Potential Role in Governing Stem Cell Homeostasis. Blood. 108: 1349-1349. DOI: 10.1182/Blood.V108.11.1349.1349  0.358
2005 Harb JG, Subramaniam M, Huettner CS. Bcl-x Is Indispensable for the Development of Natural Killer Cells. Blood. 106: 340-340. DOI: 10.1182/Blood.V106.11.340.340  0.353
2004 Harb JG, Aldstadt JH. An improved pressurized liquid extraction method for the determination of polycyclic aromatic hydrocarbons in freshwater sediments by gas chromatography-mass spectrometry Analytical Letters. 37: 2835-2850. DOI: 10.1081/Al-200032090  0.583
2003 Grundl TJ, Aldstadt JH, Harb JG, St Germain RW, Schweitzer RC. Demonstration of a method for the direct determination of polycyclic aromatic hydrocarbons in submerged sediments. Environmental Science & Technology. 37: 1189-97. PMID 12680674 DOI: 10.1021/Es020940E  0.581
Show low-probability matches.